A new study by researchers from The University of New South Wales (UNSW) in Australia suggests that health of children with a rare, high-risk cancer called neuroblastoma could be improved by adding an existing drug to their treatment plan.

The study focuses on the use of TETA (triethylenetetramine), marketed as Cuprior. This drug helps shrink tumors and boosts the immune system's ability to fight the disease. Tests on mice showed that the drug weakens tumors by transferring copper to immune cells, like neutrophils, which are white blood cells that help combat infections and diseases.